3.9 Chronic Pancreatitis & Biliary Tract Disease
Key Takeaways
- Biliary tract disease is its own blueprint subsection listing cholelithiasis, cholecystitis, choledocholithiasis, cholangitis, primary sclerosing cholangitis and sphincter of Oddi dysfunction.
- A low fecal elastase level establishes exocrine pancreatic insufficiency, which is treated with pancreatic enzyme replacement taken with meals plus fat-soluble vitamin supplementation.
- Ascending cholangitis is suggested by Charcot triad of fever, jaundice and right upper quadrant pain and requires antibiotics plus urgent biliary drainage.
- Primary biliary cholangitis presents with pruritus, fatigue and cholestatic enzymes with a positive antimitochondrial antibody, and ursodeoxycholic acid is first-line therapy.
- Primary sclerosing cholangitis shows multifocal strictures on magnetic resonance cholangiopancreatography, is strongly associated with ulcerative colitis, and has no proven medical therapy that alters survival.
Last updated: August 2026
1. Chronic Pancreatitis
Pathophysiology & Etiology
Chronic Pancreatitis is an irreversible fibro-inflammatory disease leading to destruction of exocrine parenchyma, ductal fibrosis, and loss of endocrine islets.
- TIGAR-O Classification: Toxic-metabolic (Alcohol 70–80%, Tobacco smoking is an independent, dose-dependent accelerator), Idiopathic, Genetic (PRSS1 hereditary pancreatitis causes a 40–50% lifetime risk of pancreatic adenocarcinoma; SPINK1, CFTR), Autoimmune, Recurrent/severe acute pancreatitis, Obstructive.
Clinical Presentation & Late Classic Triad
- Pancreatic Calcifications: Visible on abdominal CT or plain radiographs.
- Steatorrhea: Voluminous, greasy, foul-smelling stools due to exocrine pancreatic insufficiency (occurs when $>90%$ of exocrine function is lost).
- Pancreatogenic Diabetes (Type 3c Diabetes): Characterized by destruction of both insulin-producing $\beta$-cells and glucagon-producing $\alpha$-cells, producing labile "brittle" diabetes with high risk for severe hypoglycemia.
Diagnostic Evaluation & Management
- Diagnostic Modality of Choice for Exocrine Function: Fecal Elastase-1 ($<200;\mu\text{g/g}$ indicates exocrine insufficiency; $<100;\mu\text{g/g}$ indicates severe insufficiency). Fecal elastase-1 remains accurate while the patient is taking oral pancreatic enzymes.
- Imaging: CT demonstrates parenchymal atrophy, ductal dilatation, and coarse intraductal calcifications. Secretin-stimulated MRCP or EUS (Rosemont criteria) detects early subtle changes.
- Medical Therapy:
- Pancreatic Enzyme Replacement Therapy (PERT): Enteric-coated pancrelipase (e.g., Creon, Zenpep; high lipase doses $\ge 40,000-50,000\text{ USP units}$ per meal and half-dose with snacks) taken with the first bite of food. Add a PPI or H2RA to prevent duodenal acid inactivation if non-enteric coated.
- Pain Management: Non-opioid analgesics, pregabalin/gabapentin, celiac plexus nerve block for refractory pain.
- Lifestyle: Absolute cessation of alcohol and tobacco smoking (critical to arrest progression and decrease cancer risk).
- Fat-Soluble Vitamin Supplementation: Replete vitamins A, D, E, and K.
2. Biliary Tract Disorders
Comparative Spectrum of Gallstone Diseases
| Biliary Condition | Pathophysiology | Clinical Presentation & Physical Exam | Diagnostic Findings | Evidence-Based Management Protocol |
|---|---|---|---|---|
| Symptomatic Cholelithiasis (Biliary Colic) | Transient cystic duct obstruction by a gallstone during gallbladder contraction. | Episodic, severe, steady RUQ pain lasting $< 4-6\text{ hours}$, radiating to right shoulder/scapula. Normal vital signs; benign exam. | RUQ Ultrasound: Gallstones with acoustic shadowing; normal wall thickness ($<4\text{ mm}$); no pericholecystic fluid. Labs normal. | Outpatient Elective Laparoscopic Cholecystectomy; NSAIDs (Ketorolac/Ibuprofen) for acute colic. |
| Acute Cholecystitis | Persistent, sustained cystic duct stone impaction causing mucosal inflammation and secondary bacterial infection. | Constant severe RUQ pain lasting $> 6\text{ hours}$, fever, nausea, vomiting, Positive Murphy Sign (inspiratory arrest on RUQ palpation). | RUQ Ultrasound: Gallstones, gallbladder wall thickening $> 4\text{ mm}$, pericholecystic fluid, sonographic Murphy sign.<br/>HIDA Scan: Gold standard if US equivocal (non-visualization of gallbladder at 4h). Leukocytosis. | NPO, IV fluids, IV broad-spectrum antibiotics (e.g., Ceftriaxone + Metronidazole), and Early Laparoscopic Cholecystectomy within 24–72 hours. (Percutaneous cholecystostomy tube for high-risk surgical patients). |
| Choledocholithiasis | Migration of gallstones into the Common Bile Duct (CBD), obstructing biliary flow. | Biliary pain + Jaundice (dark urine, acholic stools), pruritus. No fever or sepsis. | Elevated Cholestatic Enzymes: Alkaline Phosphatase, GGT, Total & Direct Bilirubin. Dilated CBD on US ($>6\text{ mm}$). | High Risk: Direct Therapeutic ERCP with sphincterotomy & stone extraction, followed by cholecystectomy.<br/>Intermediate Risk: MRCP or EUS to confirm stone prior to ERCP. |
| Acute Ascending Cholangitis | Bacterial infection of an obstructed biliary tree under high intraluminal pressure; rapid bacteremia. | Charcot's Triad:<br/>1. RUQ Pain<br/>2. Jaundice<br/>3. Fever / Chills<br/>Reynolds' Pentad:<br/>+ 4. Hypotension (Shock)<br/>+ 5. Altered Mental Status | Leukocytosis, marked hyperbilirubinemia, elevated Alk Phos/transaminases, dilated biliary tree on US/CT. Blood cultures positive (E. coli, Klebsiella). | Medical Emergency: ICU admission, IV fluid resuscitation, IV Broad-Spectrum Antibiotics (e.g., Piperacillin-tazobactam), and Emergency Biliary Decompression via ERCP within 24 hours (emergent within hours if septic shock). |
Autoimmune & Cholestatic Liver Diseases: PBC vs. PSC
Primary Biliary Cholangitis (PBC) ➔ Middle-aged Women | Intrahepatic Interlobular Ducts | AMA Positive | UDCA Therapy
Primary Sclerosing Cholangitis (PSC) ➔ Young/Middle-aged Men | Intra- & Extrahepatic Ducts | Ulcerative Colitis (70-80%) | Beaded Ducts | High Cholangiocarcinoma Risk
| Disease Feature | Primary Biliary Cholangitis (PBC) | Primary Sclerosing Cholangitis (PSC) |
|---|---|---|
| Epidemiology | Females (90%), typical age 40 to 60 years. | Males (70%), typical age 30 to 50 years. |
| Pathophysiology | Autoimmune granulomatous destruction of intrahepatic interlobular bile ducts (florid duct lesions). | Progressive obliterative fibrosis and stricturing of intrahepatic AND extrahepatic bile ducts. |
| Clinical Hallmarks | Severe pruritus (often worse at night), debilitating fatigue, xanthelasma/xanthomas, hyperpigmentation. | Progressive fatigue, pruritus, fluctuating jaundice, recurrent episodes of acute ascending bacterial cholangitis. |
| Associated Diseases | Sjögren syndrome, Hashimoto thyroiditis, Scleroderma (CREST syndrome). | Inflammatory Bowel Disease (70–80% have Ulcerative Colitis). |
| Serology & Antibodies | Anti-Mitochondrial Antibodies (AMA positive $>95%$); elevated serum IgM. | p-ANCA positive (~80%); AMA negative. |
| Diagnostic Modality | Elevated Alk Phos + Positive AMA titer ($\ge 1:40$) is diagnostic without liver biopsy. | MRCP (Magnetic Resonance Cholangiopancreatography): Diagnostic gold standard showing multifocal segmental strictures and dilatations producing a "beaded" appearance of bile ducts. |
| Malignancy Risks | Osteoporosis/osteopenia, HCC in cirrhotic stage. | High risk of Cholangiocarcinoma (10–15% lifetime risk) and Colorectal Carcinoma (due to coexisting UC). |
| Surveillance Protocol | DEXA scan q2–3y, HCC ultrasound q6m if cirrhotic. | • Annual MRCP + Serum CA 19-9 for Cholangiocarcinoma.<br/>• Annual Colonoscopy with surveillance biopsies starting at PSC diagnosis for CRC. |
| First-Line Medical Therapy | Ursodeoxycholic Acid (UDCA, 13–15 mg/kg/day) slows histologic progression and prolongs transplant-free survival. Second-line: Obeticholic acid or Bezafibrate. | No effective medical therapy proven to alter disease progression (UDCA does not improve survival). Endoscopic balloon dilation of dominant strictures; Liver transplantation for end-stage disease. |
Test Your Knowledge
A 64-year-old male with a 25-year history of heavy alcohol use presents with chronic, dull postprandial epigastric pain, a 15-lb unintentional weight loss over 6 months, and frequent bulky, pale, greasy, foul-smelling stools that float in the toilet bowl. Non-contrast CT of the abdomen demonstrates marked pancreatic parenchymal atrophy with diffuse coarse calcifications throughout the pancreatic head and body. Fasting plasma glucose is 182 mg/dL. His fecal elastase-1 level is 45 mcg/g (reference: >200 mcg/g). What is the most appropriate next step in managing his gastrointestinal symptoms and malabsorption?
A
B
C
D
Test Your Knowledge
A 52-year-old female presents to the clinic with progressive generalized pruritus (most severe on her palms and soles at night) and fatigue for the past 6 months. Physical examination reveals mild scleral icterus, extensive excoriations over her extremities, and bilateral yellowish plaques on the inner canthi of her eyelids (xanthelasma). Laboratory testing reveals: Alkaline Phosphatase 560 U/L (ULN: 115 U/L), Total Bilirubin 2.1 mg/dL, AST 58 U/L, and ALT 64 U/L. Right upper quadrant ultrasound demonstrates normal liver echotexture and normal intrahepatic and extrahepatic biliary ducts without stones. Serum Anti-Mitochondrial Antibody (AMA) titer is positive at 1:320. What is the most appropriate first-line pharmacotherapy for this patient's underlying disease?
A
B
C
D